Premium
Immune response and adverse events after vaccination against SARS‐CoV ‐2 in adult patients with transfusion‐dependent thalassaemia
Author(s) -
Delaporta Polyxeni,
Terpos Evangelos,
Solomou Elena E.,
Gumeni Sentiljana,
Nitsa Evangelia,
Apostolakou Filia,
Kyriakopoulou Dimitra,
NtanasisStathopoulos Ioannis,
Papassotiriou Ioannis,
Trougakos Ioannis P.,
Dimopoulos Meletios A.,
Kattamis Antonis
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.18146
Subject(s) - medicine , vaccination , adverse effect , immunology , immune system , population , antibody , immunity , environmental health
Summary Patients with transfusion‐dependent thalassaemia (TDT) are considered an at increased‐risk population for severe and/or morbid coronavirus disease 2019 (COVID‐19) infection. Timely vaccination is the main preventive method for severe COVID‐19. Different adverse events and reactions after vaccination have been reported, with severe ones being extremely rare. Patients with TDT may have altered immunity due to chronic transfusions, iron overload and chelation therapy, and splenic dysfunction. Here, we show that adult patients with TDT following vaccination with the novel messenger RNA vaccines have mild adverse events and can produce protective antibodies comparable to the healthy population.